Gladstone’s Melanie Ott and Alex Marson Elected to the National Academy of Medicine
Physician-scientists and directors at Gladstone Institutes, Ott and Marson are honored for their pioneering achievements in science and medicine.

The center is specifically designed to overcome the “valley of death” for developing neurotherapeutics—the gap between where discoveries in academia typically end and the stage they need to achieve to attract industry partners to develop effective treatments. The center’s strategy is to target pathogenic mechanisms that are common threads cutting across more than one neurodegenerative disease. Developing therapeutics is challenging and expensive, so gifts are aggressively leveraged. For example, the center was founded with an inaugural $3.6 million gift from the Koret Foundation and Taube Philanthropies, which has been leveraged to attract over $100 million from other sources to advance the Taube/Koret Center’s research.
In turn, these funds are used strategically to advance a portfolio of therapeutic approaches through critical de-risking steps that clarify their value to potential industry partners. Forming collaborations with companies to develop therapeutics is a key metric of the center’s success. Since 2009, the center has formed myriad partnerships with biotechnology and pharmaceutical companies to create treatments for Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, ALS, frontotemporal dementia, autism, cancer, and Hirschsprung’s disease.

Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
DONATE NOW
Research in mice reveals how critical brain cells misfire in Alzheimer’s and identifies a targeted strategy to restore healthy brain rhythms.
Discover disease research, explore the latest scientific news, and connect with experts through Gladstone’s enriched digital platform.
The complex Rube Goldberg-like molecular machinery could inspire novel technology to study and treat disease.
Shipman is recognized for pioneering molecular technologies that record cellular activity, expand genome editing, and target antibiotic-resistant superbugs.
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsDiscoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreYour gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now